Drug Profile
BAT 4306F
Alternative Names: BAT4306FLatest Information Update: 31 Jan 2022
Price :
$50
*
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-Hodgkin's lymphoma
Most Recent Events
- 31 Jan 2022 Phase-II clinical trials in Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater) in China (IV) (Bio-Thera Solutions pipeline, January 2022)
- 16 Oct 2018 Bio-Thera Solutions plans a phase I trial for Non-Hodgkin's lymphoma (Second-line therapy or greater; In adults; In elderly) in China in 2018 (ChiCTR1800018900)
- 21 Apr 2018 Pharmacodynamics data from preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)